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Heart disease is a major health challenge worldwide, accounting for 1 in 3 deaths per year globally.1–3 
Therefore, there is interest in identifying mechanisms un-
derlying cardiovascular disease to design preventative strat-
egies. It is established that traditional lifestyle risk factors, 
such as smoking, an unhealthy diet, obesity, and physical 
inactivity interact with our genes to set an increased risk of 
cardiovascular disease.4 It has also become established that 
the gene-environment interaction early in life may be just 
as, if not more, important in programming heart health and 
heart disease in the offspring.5 We, and others, have shown 
that chronic fetal hypoxia, the most common consequence of 
complicated pregnancy, can trigger a fetal origin of cardiac 
dysfunction and program an increased risk of heart disease in 
the adult offspring.6–8 Several studies in animal models have 
reported increased molecular markers of oxidative stress in 
cardiovascular tissues of fetal offspring of hypoxic preg-
nancy,6–9 and we reported that maternal treatment with the 
antioxidant vitamin C prevented the developmental program-
ming of cardiovascular dysfunction in the adult offspring of 
hypoxic pregnancy in rats.6,10 Although the latter studies pro-
vide proof of principle that maternal antioxidant therapy may 
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Abstract—Integrating functional and molecular levels, we investigated the effects of maternal treatment with a xanthine 
oxidase inhibitor on the programming of cardiac dysfunction in adult offspring using an established rat model 
of hypoxic pregnancy. Female Wistar rats were divided into normoxic or hypoxic (13% O2) pregnancy±maternal 
allopurinol treatment (30 mg kg-1 d-1). At 4 months, hearts were isolated from 1 male per litter per outcome variable 
to determine cardiac function and responses to ischemia-reperfusion in a Langendorff preparation. Sympathetic 
dominance, perfusate CK (creatine kinase) and LDH (lactate dehydrogenase) and the cardiac protein expression of the 
β1-adrenergic receptor, the M2 Ach receptor (muscarinic type-2 acetylcholine receptor), and the SERCA2a (sarcoplasmic 
reticulum Ca2+ ATPase 2a) were determined. Relative to controls, offspring from hypoxic pregnancy showed elevated 
left ventricular end diastolic pressure (+34.7%), enhanced contractility (dP/dt
max
, +41.6%), reduced coronary flow rate 
(−21%) and an impaired recovery to ischemia-reperfusion (left ventricular diastolic pressure, area under the curve 
recovery −19.1%; all P<0.05). Increased sympathetic reactivity (heart rate, +755.5%; left ventricular diastolic pressure, 
+418.9%) contributed to the enhanced myocardial contractility (P<0.05). Perfusate CK (+431%) and LDH (+251.3%) 
and the cardiac expression of SERCA2a (+71.4%) were also elevated (P<0.05), further linking molecular markers of 
cardiac stress and injury to dysfunction. Maternal allopurinol restored all functional and molecular indices of cardiac 
pathology. The data support a link between xanthine oxidase–derived oxidative stress in hypoxic pregnancy and 
cardiac dysfunction in the adult offspring, providing a target for early intervention in the developmental programming 
of heart disease.  (Hypertension. 2018;72:971-978. DOI: 10.1161/HYPERTENSIONAHA.118.11363.) • Online 
Data Supplement
Key Words: allopurinol ◼ developmental programming ◼ hypoxia ◼ oxidative stress ◼ pregnancy ◼ rats
Maternal Allopurinol Prevents Cardiac Dysfunction in Adult 
Male Offspring Programmed by Chronic Hypoxia  
During Pregnancy
Youguo Niu, Andrew D. Kane, Ciara M. Lusby, Beth J. Allison, Yi Yi Chua,  
Joepe J. Kaandorp, Rhiannon Nevin-Dolan, Thomas J. Ashmore, Heather L. Blackmore,  
Jan B. Derks, Susan E. Ozanne, Dino A. Giussani
© 2018 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access 
article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the 
original work is properly cited.
Hypertension is available at https://www.ahajournals.org/journal/hyp DOI: 10.1161/HYPERTENSIONAHA.118.11363
Fetal Programmimg
D
ow
nloaded from
 http://ahajournals.org by on September 27, 2018
972  Hypertension  October 2018
protect cardiac function in the adult offspring of complicated 
pregnancy, only high doses of vitamin C incompatible with 
human clinical translation proved effective.6,10
An alternative antioxidant strategy of improved transla-
tional value to human clinical therapy may be the xanthine 
oxidase inhibitor allopurinol. Hypoxia leads to an increase 
in xanthine oxidase–derived free radical generation,11 and 
in humans, maternal treatment with allopurinol crosses the 
placenta,12 justifying this route of administration for preven-
tative therapy in obstetric practice. It has been suggested 
that allopurinol has beneficial effects in reducing ischemia-
reperfusion (IR) damage in adult cardiology and in pediatric 
and adult cardiothoracic surgery.13,14 Indeed, maternal allo-
purinol treatment is currently being considered in human 
clinical trials to protect the newborn infant from oxidative 
stress–induced injury in pregnancy complicated by fetal 
hypoxia.15
Recently, we established a rat model in which maternal 
oral treatment with allopurinol yields circulating concentra-
tions in the fetus similar to those reported in a human clin-
ical context and suppresses xanthine oxidase activity in the 
maternal, placental, and fetal tissues.16 However, whether 
maternal oral treatment with this dosing regimen of allo-
purinol protects against programmed cardiac dysfunction 
in the adult offspring in hypoxic pregnancy is not known. 
Therefore, this study tested the hypothesis that maternal 
allopurinol treatment is protective against programmed 
cardiac dysfunction in adult male offspring of hypoxic 
pregnancy. This was tested using an established rat model 
by investigating the effect of hypoxic pregnancy with and 
without maternal allopurinol treatment on basal and stim-
ulated cardiac function and on the cardiac response to IR 
in the adult male offspring using an isolated Langendorff 
preparation. To address mechanisms mediating changes in 
cardiac reactivity, cardiac responses to increasing doses of 
selective muscarinic and β1-adrenergic agonists were inves-
tigated, and alterations in the protein expression of the β1-
adrenergic and the M2 Ach receptors (muscarinic type-2 
acetylcholine receptors) were determined. To further link 
molecular mechanisms to cardiac dysfunction, perfusate 
concentrations of CK (creatinine kinase) and LDH (lactate 
dehydrogenase) and the cardiac expression of the SERCA2a 
(sarcoplasmic reticulum Ca2+ ATPase 2a), common markers 
of cardiac stress and injury, were also established.
Methods
Data, Materials, and Code Disclosure Statement
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Ethical Approval
This research was approved under the Animals (Scientific Procedures) 
Act 1986 Amendment Regulations 2012 after ethical review by the 
University of Cambridge Animal Welfare and Ethical Review Board.
Animals
Wistar rats (Charles River, Ltd, Margate, United Kingdom) were 
housed individually in ventilated cages under standard conditions 
with free access to food (Special Diet Services, United Kingdom) 
and water. After 10 days of acclimatization, virgin females (n=56, 
10–12 weeks of age) were paired with fertile male rats (minimum 12 
weeks of age). The presence of a copulatory plug was considered day 
0 of pregnancy (term is ca. 21 days).
Hypoxic Pregnancy and Maternal Allopurinol 
Treatment
On day 6 of pregnancy, rats were divided using a random number 
generator into 4 groups (n=12 per group): normoxic and hypoxic 
pregnancy, with or without maternal oral allopurinol treatment (30 
mg kg-1 d-1 in vehicle jelly). Hypoxia exposure and allopurinol treat-
ment was from day 6 to 20 of gestation. The jelly containing allo-
purinol and the vehicle jelly were undistinguishable, but they were 
coded. Experimenters assigning treatment and analysing the data 
were unaware of the meaning of the code until all experiments and 
data analyses were completed. Scientists were, therefore, blinded 
to the group allocation. We have established that this maternal al-
lopurinol treatment in rat pregnancy crosses the placenta, leads to 
therapeutic concentrations of allopurinol and its active metabolite 
oxypurinol in the fetal circulation, and suppresses xanthine oxidase 
activity in the mother, placenta, and fetus.16,17 Pregnant rats subjected 
to hypoxia were placed inside a transparent chamber, which received 
air and nitrogen to required mixture.6 The chamber could house 9 
rat cages in a tranquil environment.6 Pregnancies undergoing hy-
poxia were maintained at 13% O2 from day 6 to 20 of gestation. This 
level of hypoxia equates to ≈3600 m, the altitude at which pregnancy 
complications significantly increase in human populations.18,19 This 
level of maternal hypoxia also leads to levels of fetal hypoxia asso-
ciated with complications in sea level human pregnancy.20,21 We have 
previously reported that this level and duration of maternal hypoxia 
does not lead to alternations in maternal food intake.6 The onset of 
hypoxia was on day 6, as preliminary studies revealed, markedly 
enhanced pregnancy loss if the hypoxia started earlier.6 At birth, each 
pup within each litter was sexed by measurement of anogenital dis-
tance and pups were weighed and culled to 8 per litter to standardize 
feeding and maternal care.
Langendorff Heart Preparation
All pups remained with their mothers until weaning at postnatal day 
21. After weaning, pups were group-housed under standard condi-
tions and maintained until 4 months of age. At 4 months, to control 
for sex and within-litter variation, only 1 male pup per litter was used 
for each outcome. Unused offspring were donated to other studies. 
Adult males underwent euthanasia by CO2 inhalation and posterior 
cervical dislocation. The heart was rapidly excised, immediately 
placed in ice-cold Krebs-Henseleit bicarbonate buffer, and then 
mounted onto a Langendorff preparation, used routinely in our lab-
oratory.22 In brief, a recirculating Krebs-Henseleit bicarbonate buffer 
solution containing (mmol/L) 120 NaCl, 4.7 KCl, 1.2 MgSO2.7H2O, 
1.2 KH2PO4, 25 NaHCO3, 10 glucose, and 1.3 CaCl2.2H2O was fil-
tered through a 5 μm cellulose nitrate filter (Millipore, Bedford, MA) 
and gassed with O2:CO2 (95:5) at 37°C. Isolated hearts were perfused 
in retrograde fashion through the aorta at a constant pressure (100 
cm H2O). A small flexible nonelastic balloon was inserted into the 
left ventricle (LV) through the left atrium. The balloon was filled 
with distilled water, and its volume was adjusted to 150 μl to obtain 
an LV end-diastolic pressure (LVEDP) recording between 5 and 10 
mm Hg.22 After 15-minute stabilization, basal heart rate, LV systolic 
pressure, and LVEDP were recorded. Basal LV developed pressure 
(LVDP) was calculated as LV systolic pressure–LVEDP. The max-
imum and minimum first derivatives of the LV pressure (dP/dt
max
 and 
dP/dt
min) were calculated. Coronary flow rate was calculated by timed 
collections of perfusate.22
Cardiac Stimulated Function: Agonists  
and IR Challenge
The cardiac responsiveness to the muscarinic agonist Carbachol 
(carbamylcholine chloride, Sigma-Aldrich, Co, Ltd, Poole, United 
Kingdom; range, 10-10–10-6 mol/L) and the β1-adrenoreceptor 
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agonist isoprenaline ([−]-isoprenaline [+]-bitartrate salt, Sigma-
Aldrich, Co, Ltd, Poole, United Kingdom; range, 10–11–10-7 mol/L) 
were investigated as described before.22 After the final dose re-
sponse, when heart rate and LVDP recovered back to the baseline, 
the hearts were subjected to an IR challenge composed of 10 min-
utes of global ischemia by stopping the perfusion, followed by 30 
minutes of reperfusion.
CK and LDH Activity
The coronary effluent (2 mL) was collected before ischemia (−15 
minutes) and at the onset of reperfusion (0 minutes). Samples were 
immediately frozen in liquid nitrogen and kept at −80°C until anal-
ysis. Perfusate CK activity was analyzed using a bichromatic coupled 
enzyme reaction assay (Siemens Dimension RxL analyser, Malvern, 
PA). Perfusate LDH activity was analysed using a colorimetric assay 
(Siemens Dimension RxL analyser, Malvern, PA).
Cardiac Protein Expression
At 4 months of age, the heart from a male sibling from each litter was 
isolated, frozen in liquid nitrogen, and kept at −80°C. Protein expres-
sion of the cardiac β1-adrenergic receptor, the M2 Ach receptor, and 
the SERCA2a was determined by Western blot;23 10 µg of protein 
were loaded for each sample. Equal protein loading was confirmed 
by Coomassie blue staining. Antibodies used were β1-adrenergic 
receptor (Santa Cruz Biotechnology, Dallas, TX), M2 Ach receptor (Abcam, Cambridge, United Kingdom), and the cardiac SERCA2a, 
Cell Signaling, Danvers, MA). Horseradish peroxidase-linked second 
antibody (Jackson ImmunoResearch) binding was detected using 
Super15 Signal West Pico Chemiluminescent substrate (Thermo 
Scientific, United Kingdom). Autoradiographed images were quanti-
fied using AlphaEase (Alpha Innotech).
Statistical Analysis
Appropriate power calculations derived from previous data sets 
were performed to determine the minimum sample size required to 
achieve statistical significance set at P<0.05. Data are expressed as 
mean±SEM. Data were compared statistically by 2-way ANOVA, 
with hypoxia and allopurinol treatment as 2 between-subjects 
factors. The Tukey post hoc test was used to isolate significant 
differences.
Results
Basal Cardiac Function
Adult male offspring of hypoxic pregnancy showed elevated 
LVEDP with no change in LVDP (Figure 1A and 1B), a signif-
icant increase in dP/dt 
max
 with no change in dP/dt 
min (Figure 1C 
and 1D), and impaired coronary flow rate (Figure 1E and 
1F). Maternal allopurinol prevented the increase in LVEDP 
and in dP/dt
max
 and the fall in coronary flow rate (Figure 1A, 
1C, 1E, and 1F). Maternal allopurinol treatment in normoxic 
pregnancy did not affect basal function in hearts of adult male 
offspring (Figure 1A through 1F).
Cardiac Responses to Autonomic Agonists
Hearts of adult male offspring of normoxic pregnancy showed 
dose-dependent chronotropic (heart rate) and inotropic 
(LVDP) responses to agonists (Table S1 in the online-only 
Data Supplement). Adult male offspring of hypoxic pregnancy 
showed diminished cardiac negative chronotropic and ino-
tropic responses to carbachol, whereas significantly enhanced 
positive chronotropic and inotropic responses to isoprenaline 
(Table S1). Consequently, the ratio of the maximal responses 
to Isoprenaline relative to those of carbachol was markedly 
increased (Figure 2). Hearts of adult male offspring of hy-
poxic pregnancy treated with allopurinol no longer showed 
these effects (Table S1 and Figure 2). Hearts of adult male off-
spring of normoxic pregnancy treated with allopurinol showed 
an impaired inotropic response to carbachol (Table S1).
Ischemia/Reperfusion Challenge
Adult male offspring of hypoxic pregnancy showed an im-
paired cardiac recovery to IR (Figure 3A) and enhanced CK 
and LDH effluent levels (Figure 3B and 3C) at the onset of re-
perfusion. Adult male offspring of hypoxic pregnancy treated 
with allopurinol showed a restored cardiac recovery response 
to IR and normalized CK and LDH (Figure 3A through 3C).
Cardiac Protein Expression
Adult male offspring of hypoxic pregnancy showed an increased 
cardiac protein expression of SERCA2a without any significant 
effects on β1-adrenergic or muscarinic type-2 receptor expres-
sion (Figure 4A through 4C). Adult male offspring of hypoxic 
pregnancy treated with allopurinol showed restored cardiac 
protein expression of SERCA2a (Figure 4A). Adult male off-
spring of normoxic pregnancy treated with allopurinol showed 
an enhanced cardiac protein expression of SERCA2a relative 
to hearts of adult male offspring of untreated normoxic preg-
nancy (Figure 4A) with no effects on the protein expression of 
β1-adrenergic or muscarinic type-2 receptors.
Pregnancy Characteristics and Offspring Biometry
Values for gestation length, litter size and for the male to fe-
male ratio were not different between groups (Table). Hypoxic 
pregnancy did not affect birth weight or the symmetry of body 
growth. Relative to normoxic pregnancy, hearts of adult male 
Figure 1. Cardiac basal function. Values are 
dot plots, as well as mean±SEM. Groups are 
normoxic (N; n=9), hypoxic (H; n=8), hypoxic 
treated with allopurinol (HA; n=8), and normoxic 
treated with allopurinol (NA; n=9) pregnancy. 
Significant differences (P<0.05) are *vs N; †vs 
H (2-way ANOVA+Tukey test). CFR indicates 
coronary flow rate; dP/dt max and dP/dt min, the 
maximum and minimum first derivatives of 
the left ventricular pressure; HW, heart weight; 
LVDP, left ventricular developed pressure; and 
LVEDP, left ventricular end diastolic pressure.
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offspring of hypoxic pregnancy were of similar weight, but 
the absolute weight of the left ventricle was reduced (Table). 
Maternal allopurinol in hypoxic pregnancy did not affect the 
pregnancy characteristics or the male offspring biometry, and 
it did not restore the reduction in absolute LV weight meas-
ured in adult male offspring of untreated hypoxic pregnancy 
(Table). Maternal treatment with allopurinol in normoxic 
pregnancy did not have any effects (Table).
Discussion
We show that maternal treatment with allopurinol using a 
dose regimen that inhibits xanthine oxidase activation in the 
maternal, placental, and fetal tissues restores all functional 
and molecular markers of cardiac pathology in adult male 
offspring of hypoxic pregnancy. Mechanisms contributing 
to the enhanced cardiac contractility in hearts of adult male 
offspring of hypoxic pregnancy include a programmed in-
crease in cardiac sympathetic dominance. This is character-
ized by reciprocal effects on the cardiac responsiveness to 
β1-adrenergic and muscarinic receptor stimulation, without 
affecting their receptor protein expression. Mechanisms con-
tributing to alterations in basal cardiac function in adult male 
offspring of hypoxic pregnancy also include an increase in the 
protein expression of SERCA2a, indicating a reorganization 
of cardiac Ca2+ management. The activities of CK and LDH 
in the coronary perfusate after IR in adult male offspring of 
hypoxic pregnancy were also elevated, thereby, linking mo-
lecular markers of cardiac stress and injury to the increased 
cardiac susceptibility to IR injury (Figure 5).
Elevated LVEDP in the present study suggests impaired 
LV relaxation during diastole, indicative of cardiac diastolic 
dysfunction and increased cardiac stiffness, both of which are 
associated with increased mortality resulting from a cardiac 
event.24 In an elegant study, Rueda-Clausen et al8 also reported 
echocardiographic evidence of elevated LVEDP without sig-
nificant effects on LVDP in adult rat offspring of hypoxic 
pregnancy. Elevated LVEDP is an important index because, 
clinically, cardiac diastolic dysfunction often precedes systolic 
dysfunction.25 The elevated diastolic pressure in hearts of male 
offspring of hypoxic pregnancy is likely because of increased 
diastolic Ca2+. The increase in cardiac SERCA upregula-
tion also evident in the male offspring of hypoxic pregnancy 
may, therefore, be a compensatory mechanism to offset the 
increase in diastolic Ca2+. The mechanism underlying the in-
crease in diastolic Ca2+ includes an enhanced RyR (ryanodine 
receptor) leak, also known to be exacerbated by the upregula-
tion of SERCA, which will increase sarcoplasmic reticulum 
Ca2+ load and thereby release.26,27 In turn, an increase in sarco-
plasmic reticulum Ca2+ release will lead to greater contractility 
by increasing the amplitude of the Ca2+ transient. The latter is 
consistent with the significantly greater increase in dP/dt
max
 in 
hearts of offspring of hypoxic pregnancy in the present study.
Additional data in the present study show increased sym-
pathetic dominance in hearts of male offspring of hypoxic 
pregnancy. The increase in cardiac protein levels of SERCA2a 
in offspring from hypoxic pregnancy may again be involved in 
this programmed response, as SERCA2a promotes an increase 
in cardiac contractility and stimulation of cardiac β-adrenergic 
receptors phosphorylates and inactivates phospholamban, an 
inhibitor of SERCA.28 Increased cardiac sympathetic domi-
nance is part of a compensatory neuroendocrine mechanism to 
increase myocardial contractility and maintain cardiac output 
Figure 2. Cardiac sympathetic dominance. 
Values are dot plots, as well as mean±SEM for 
the ratio of cardiac chronotropic and inotropic 
responses to isoprenaline and carbachol. 
Groups are normoxic (N; n=9), hypoxic (H; n=8), 
hypoxic treated with allopurinol (HA; n=8), and 
normoxic treated with allopurinol (NA; n=9) 
pregnancy. Significant differences (P<0.05) are 
*vs N; †vs H (2-way ANOVA+Tukey test). HR 
indicates heart rate; and LVDP, left ventricular 
developed pressure.
Figure 3. Cardiac ischemia-reperfusion challenge. Values are dot plots or mean±SEM for the cardiac left ventricular developed pressure (LVDP) response 
to ischemia-reperfusion and the perfusate CK (creatine kinase) and LDH (lactate dehydrogenase) levels. Groups are normoxic (N; n=9), hypoxic (H; n=8), 
hypoxic treated with allopurinol (HA; n=8), and normoxic treated with allopurinol (NA; n=9) pregnancy. Significant differences (P<0.05) are *vs N; †vs H (2-way 
ANOVA+Tukey test).
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in the young adult offspring of hypoxic pregnancy. However, 
such compensatory responses may become decompensated 
later in life, as sustained increases in sympathetic dominance 
and myocardial contractility are unsustainable, triggering del-
eterious effects on cardiac function and leading eventually to 
heart failure.29,30
A reduction in basal coronary flow rate has been linked 
with an increased risk of cardiac injury in response to IR.30,31 
Consistent with this statement, hearts of adult male offspring 
of hypoxic pregnancy had an impaired IR recovery and 
enhanced LDH and CK in the coronary effluent after ischemia. 
LDH is involved in glucose metabolism and catalyzes the in-
terconversion of lactate and pyruvate, whereas CK catalyses 
the conversion of creatine to phosphocreatine, responsible for 
ATP transfer and utilization. When cardiomyocytes are dam-
aged, LDH and CK are released from the cytoplasm into the 
bloodstream, an effect that has been exploited clinically as es-
tablished biomarkers for cardiac injury.7,31 An increase in the 
effluent levels of LDH and CK immediately after ischemia is, 
therefore, strong evidence for an increased risk of IR injury in 
hearts of offspring of hypoxic pregnancy.
We, and others, have previously reported that pregnancy 
complicated by chronic hypoxia programmes cardiac dysfunc-
tion in the adult offspring secondary to the generation of oxida-
tive stress in the fetal cardiovascular system.6–9 By adulthood, 
levels of oxidative stress in the cardiovascular system are no 
longer different between groups. However, present data show 
that hypoxic pregnancy sets a functional deficit in the hearts of 
male offspring even by early adulthood with evidence of dias-
tolic dysfunction, sympathetic dominance, and increased myo-
cardial susceptibility to IR injury. Data in the present study show 
that xanthine oxidase–derived oxidative stress contributes to the 
programming of this cardiac dysfunction in adult male offspring 
of hypoxic pregnancy. Xanthine oxidase and its precursor, XDH 
(xanthine dehydrogenase), both catalyze the conversion of hy-
poxanthine to xanthine and xanthine to uric acid. They differ in 
Figure 4. Cardiac proteins expression. Values 
are dot plots, as well as mean±SEM. Groups 
are normoxic (N; n=6), hypoxic (H; n=6), 
hypoxic treated with allopurinol (HA; n=6), and 
normoxic treated with allopurinol (NA; n=6) 
pregnancy. Significant differences (P<0.05) 
are *vs N; †vs H (2-way ANOVA+Tukey test). 
SERCA2A indicates sarcoplasmic reticulum 
Ca2+ ATPase 2a.
Table. Pregnancy Characteristics and Offspring Biometry
Outcome Variable N H HA NA
Days of gestation 22.0±0.1 22.1±0.1 22.2±0.1 22.0±0.1
Litter size 13.4±0.5 13.5±0.5 12.5±0.6 14.2±0.5
Male:female ratio 0.9±0.2 0.9±0.2 1.1±0.2 1.2±0.2
Birth weight, g 6.3±0.1 6.4±0.2 6.4±0.2 6.2±0.1
Body weight at 4 mo, g 568.3±13.6 549.9±17.5 556.2±11.5 546.5±11.8
CRL, cm 23.9±0.2 22.7±0.3 23.0±0.3 23.1±0.2
PI, kg.(m3)-1 43.5±1.0 45.2±1.4 44.2±1.4 44.6±1.5
Heart weight at 4 mo
  whole
   abs, g 2.05±0.07 1.91±0.05 1.95±0.07 1.99±0.08
   rel, % 0.34±0.01 0.36±0.01 0.37±0.01 0.36±0.01
  LV+septum
   abs, g 1.30±0.04 1.13±0.05* 1.18±0.04* 1.24±0.05
   rel, % 63.51±0.83 59.18±1.33 60.91±2.39 62.22±1.30
  RV
   abs, g 0.35±0.01 0.35±0.01 0.35±0.02 0.35±0.02
   rel, % 17.29±0.40 18.08±0.60 18.00±0.86 17.44±0.77
Values are mean±SEM for maternal and offspring variables. Groups are N (n=10–17), H (n=8–21), HA 
(n=8–22), and (NA, n=10–17) pregnancy. abs indicates absolute weight; CRL, crown-rump length; H, hypoxic; 
HA, hypoxic treated with allopurinol; LV, left ventricle; N, normoxic; NA, normoxic treated with allopurinol ; PI, 
ponderal index (body weight.[CRL3]-1); rel, relative weight; and RV, right ventricle.
*Significant differences (P<0.05) are H and HA vs N, (2-way ANOVA+Tukey test).
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that XDH utilises NAD+ (oxidized nicotinamide adenine dinu-
cleotide) preferentially as the electron acceptor, whereas xan-
thine oxidase only reduces oxygen, resulting in the concomitant 
generation of the superoxide anion and hydrogen peroxide.32 
Xanthine oxidase becomes a powerful pro-oxidant mechanism 
stimulated by chronic hypoxia, primarily because of facilitated 
conversion of XDH to xanthine oxidase and the accumulation of 
the substrate hypoxanthine.33 The gene expression of xanthine 
oxidase and XDH is also regulated by oxygen tension, which 
is activated by hypoxia and inhibited by hyperoxia.34 Therefore, 
maternal treatment with allopurinol by inhibiting xanthine ox-
idase activity in the fetoplacental unit may offer therapeutic 
potential to prevent the programming of cardiac dysfunction in 
adult offspring of pregnancies complicated by hypoxia. Indeed, 
increased sympathetic dominance in hearts of adult offspring 
seems to be a common programming mechanism in several types 
of adverse pregnancy, for instance, in maternal obesity during 
pregnancy.23 Therefore, maternal allopurinol may protect against 
cardiovascular dysfunction in the adult offspring programmed 
by several types of adverse pregnancy. In the present study, it 
is of additional interest that hearts of adult offspring from hy-
poxic pregnancies treated with allopurinol appeared to recover 
better from a period of IR, in terms of LVDP, compared with 
hearts from untreated and treated control pregnancies. This may 
be because of additional cardioprotective effects of allopurinol. 
For instance, evidence from animal models and human clinical 
studies report that in addition to its antioxidant properties, al-
lopurinol enhances cardiac energy and mechanical efficiency 
by decreasing myocardial oxygen consumption, particularly in 
the failing heart.35,36 Maternal allopurinol treatment is currently 
being considered in human clinical trials to protect the newborn 
infant from oxidative stress–induced injury in pregnancy com-
plicated by fetal hypoxia.15 Here, we show that maternal allo-
purinol transcends beneficial effects on the newborn infant to 
also protect against the programming of cardiac dysfunction in 
the male offspring. These findings are of significant human clin-
ical importance as offspring of complicated pregnancy, despite 
the absence of intrauterine growth restriction and reduced birth 
weight, have been reported to already show cardiac dysfunction 
as children.37 A component of this cardiac dysfunction in chil-
dren programmed by adverse intrauterine conditions may thus 
involve xanthine oxidase activation.
This study has limitations. Only male offspring were inves-
tigated to control for sex differences but not to address them. 
Maternal treatment with allopurinol in normoxic pregnancy also 
led to an increase in the cardiac protein levels of SERCA2a in 
Figure 5. Summary of key findings. Hypoxic pregnancy programmes cardiac dysfunction in adult male offspring. Mechanisms involved include an 
increase in xanthine oxidase, cardiac sympathetic dominance, and altered cardiac calcium biology. Maternal treatment with the xanthine oxidase 
inhibitor, allopurinol, prevents the programmed cardiac dysfunction in adult male offspring, normalizing the cardiac sympathetic dominance and altered 
cardiac calcium biology. Therefore, oxidative stress derived from xanthine oxidase plays an important role in the programming of cardiac dysfunction 
by developmental hypoxia. Maternal treatment with allopurinol should be considered as clinical intervention against the programming of heart disease 
in adult offspring of human high-risk pregnancy. IR indicates ischemia-reperfusion; LV, left ventricle; ROS, reactive oxygen species; and SERCA2a, 
sarcoplasmic reticulum Ca2+ ATPase 2a.
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the adult male offspring. The mechanism underlying this effect 
is not clear and further studies are required to address this. 
However, this effect was not matched by an increase in LVEDP 
or sympathetic dominance in hearts of adult male offspring of 
normoxic pregnancy treated with allopurinol. Therefore, ma-
ternal treatment with allopurinol should only be given to those 
who need it; that is in pregnancy diagnosed with chronic fetal 
hypoxia rather than to all pregnancies. This may not be feasible 
if risk cannot be identified before administration. Current ob-
stetric opinion is that, in human pregnancy, chronic fetal hy-
poxia can be reliably diagnosed by ultrasound between 20 and 
26 weeks of gestation, according to severity. Diagnosis encom-
passes early onset fetal growth restriction with reduced fetal 
heart rate variability and abnormal Doppler blood flow velo-
cimetry indices, such as in those human pregnancies recently 
recruited to the EVERREST (Developing a Therapy for Fetal 
Growth Restriction) or TRUFFLE (Trial of Umbilical and Foetal 
Flow in Europe) studies.38,39 However, it must be highlighted that 
all these measurable outcomes are surrogate indices associated 
with rather than direct measures of chronic fetal hypoxia. There 
is, therefore, a need for further study and for clinical discussion 
to address these important limitations before translation.
Perspectives
Developmental hypoxia, the most common outcome in human 
adverse pregnancy programmes an increased risk of heart di-
sease in the adult offspring. Using an established rodent model, 
here, we show that xanthine oxidase–derived oxidative stress 
links developmental hypoxia with cardiac dysfunction and with 
molecular mechanisms of cardiac stress and injury in the adult 
offspring. In addition, maternal treatment with allopurinol is 
protective. Therefore, targeted inhibition of xanthine oxidase–
derived oxidative stress may offer improved translational value 
to human clinical therapy to prevent the programming of car-
diac dysfunction in offspring of high-risk pregnancy.
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What Is New?
•	Chronic fetal hypoxia, the most common complication in adverse preg-
nancy in humans, programmes cardiovascular dysfunction in the adult 
offspring. However, few studies have addressed mechanism and thereby 
intervention.
•	We show that xanthine oxidase–derived oxidative stress links hypoxic 
pregnancy with programmed cardiovascular dysfunction in the adult off-
spring and that maternal treatment with allopurinol is protective.
What Is Relevant?
•	 It is now accepted that the gene-environment interaction early in life may 
be just as, if not more, important in programming cardiovascular health 
and disease, including hypertension.
•	Therefore, when considering strategies to reduce the burden of cardi-
ovascular disease, a greater focus on prevention rather than treatment 
is needed and for candidate interventions to start as early as possible 
during the developmental trajectory rather than to wait until disease is 
established and irreversible.
Summary
In this translational science study, we show that maternal treat-
ment with allopurinol in adverse pregnancy protects against in-
creased risk of heart disease in the adult offspring.
Novelty and Significance
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